Compare Tango Therapeutics Inc. (TNGX) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Zoom Video Communications, Inc. — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while Zoom Video Communications, Inc. trades at $93.87 (market cap $28.64B). The key difference: Zoom Video Communications, Inc. is far larger — about 7.6× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 2,595,677). Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Zoom Video Communications, Inc. for 92 Days on average.
| TNGX | ZM | |
|---|---|---|
Market Cap | $3.75B | $28.64B |
Volume | 9,619,106 | 2,595,677 |
Sector | Health | Technology |
52-Week High | $32.90 | $111.88 |
52-Week Low | $7.50 | $72.72 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $2.77B | $21.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Zoom Communications (ZM) trades at $94.47, down 3.54% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $118.08. The company reported strong profitability with a net income margin of 65.19% in 2026 and is advancing its AI-powered revenue OS, positioning for growth amid recent earnings beats.
The stock presents a compelling opportunity given its attractive valuation (P/E of 9.11) and robust fundamentals, though risks include reliance on international sales and competitive pressures in the communication software sector. Upside potential exists if the company executes on its AI initiatives and maintains earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
